

**Enterprise P&T Meeting
Committee Meeting Minutes
January 31, 2022**

Voting Members Present

Antypas, Christopher, PharmD	Davis, Tracey, PharmD	Hockmuth, Robert, MD	Muller, Betty, MD	Robinson, Michelle, PharmD
Batluck, David, DO	Elebra, Rogers, PharmD	Kryger, Emily, PharmD	Orr, Lavdena, MD	Smith, Kirby, MD
Brinley, Floyd (John), MD	Feconda, Fury, PharmD	Martin, Kelly, PharmD	Peters, Eric, PharmD	Weart, Wayne, PharmD
Caton, Kirt, MD	Higgins, Lily, MD	McAllister, Susan, MD	Peterson, Andrew, PharmD	Whitfield, Rani, MD
Cooper, Don, MD	Himmelstein, Bruce, MD	Michael, Kendra, MD	Petkash, David, MD	Wise, Rodney, MD

Excused Voting Members

Beam, Donald, MD		

Invited Guests Present

Broussard, Rachel			
Guerrero, Monica			

Issue	Discussion	Conclusion/Results	Vote	Action/ Person Responsible
1. Call to Order	The meeting was called to order at 6:00 PM EST Welcomed all external and internal participants.	Informational Only		Bruce Himelstein
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only		Sheena Cherian
3. Enterprise P&T Charter and Conflict of Interest Training		Committee approved as recommended Motion: Rob Hockmuth Second: David Hamlin		Sheena Cherian
4. [REDACTED]		[REDACTED]		[REDACTED]
5. Review and approval of October P&T Minutes		Committee approved as recommended Motion: Donald Cooper Second: Kirt Caton		Sheena Cherian
6. Old Business				
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<ul style="list-style-type: none">- [REDACTED]- [REDACTED]			
	<ul style="list-style-type: none">- [REDACTED]- [REDACTED]- [REDACTED]			
	<ul style="list-style-type: none">- [REDACTED]- [REDACTED]- [REDACTED]			
	<ul style="list-style-type: none">- [REDACTED]			

	<ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED]			
[REDACTED]	<ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	<ul style="list-style-type: none">[REDACTED]	[REDACTED]		[REDACTED]








	<p>[REDACTED]</p> <p>[REDACTED]</p>			
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]	█ [REDACTED]		
█ [REDACTED]	█ [REDACTED]	█ [REDACTED]		█ [REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>

				
7. New Business				
Anti-CD19 CAR-T Immunotherapies	<p>PerformRx makes the following recommendation:</p>  <p>  </p> <p> CHC:</p>	<p>Committee approved as recommended</p> <p>Motion: Tracey Davis Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>	

	<ul style="list-style-type: none"> • Include additional authorization criteria for Tecartus for ALL aligned with package insert <p>[REDACTED]</p>			
LAI Antipsychotics Specialty Update	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Remove the specialty designation and update the formulary status as noted below for Long Acting Injectable Antipsychotics <p>[REDACTED]</p>	<p>Tabled to determine impact and process for making updates</p>		<p>No Changes</p>
Synagis	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Tracey Davis Second: Donald Cooper</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Change the maximum allowed doses per season to 7 due to extended 2021-2022 RSV season and updated American Academy of Pediatrics guidance.			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
8. Drug Reviews				
A. Therapeutic Class				
First Generation Antihistamines	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Andrew Peterson</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Remove Diphenhydramine 50 mg/mL IV vial from the formulary due to a lack of utilization• Remove Hydroxyzine 25mg/mL, 50 mg/mL IM solution from the formulary due to a lack of utilization <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
New Cardiovascular Drugs	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Andrew Peterson</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- Remove the following products from the formulary based on the low utilization and availability of more cost effective alternatives on the formulary:
 - a. iron 18 mg tablet
 - b. ferrous sulfate 134 mg (27 mg iron) tablet
 - c. Slow Release Iron (ferrous sulfate, dried) 168 mg (50 mg iron) tablet, extended release
 - d. ferrous sulfate 250 mg (50 mg iron) tablet, extended release
 - e. ferrous sulfate 300 mg (60 mg iron)/5 mL oral liquid
 - f. ferrous gluconate 236 mg (27 mg iron) tablet
 - g. ferrous gluconate 256 mg (28 mg iron) tablet

[REDACTED]

PerformRx makes the following recommendation:

[REDACTED]

Committee approved as recommended

Motion: Rani Whitfield

Antitussives and Expectorants

No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• No changes to the formulary statuses for these medications <p>[REDACTED]</p>	Second: Chris Meny		
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
--	-------------------------------------	--	--	--

	<p>[REDACTED]</p>			
<p>B. Single Products</p>				
<p>Methergine</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Lavdena Orr Second: Kirby Smith</p>		<p>No changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• No changes to the formulary status for Methergine <p>[REDACTED]</p>			
Tavneos	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Lavdena Orr Second: Kirby Smith</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>█ █ █</p> <p>CHC:</p> <ul style="list-style-type: none">• Add Tavneos (avacopan) to Tier 4 with a prior authorization requirement.• Implement the newly developed Tavneos (avacopan) prior authorization criteria <p>█ █ █</p>			
Phexxi	<p>PerformRx makes the following recommendation:</p> <p>█ █ █</p> <p>█ █ █</p> <p>█</p>	<p>Committee approved as recommended</p> <p>Motion: Lavdena Orr Second: Kirby Smith</p>		<p>No changes</p>

	<p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• No changes to the formulary status of Phexxi (lactic acid and potassium bitartrate) <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>			
Limvarli	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Lavdena Orr Second: Kirby Smith</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
--	---	--	--	--

[REDACTED]

CHC

- Add Livmarli (maralixibat) to tier 4 with a prior authorization requirement
- Approve the updated Ileal Bile Acid Transporter Inhibitor (IBAT) prior authorization criteria
 - Include approval criteria Livmarli
 - Add colesevelam as an additional trial alternative
 - Language changes for clarity

[REDACTED]

9. New Products

PerformRx makes the following recommendation:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Committee approved as recommended

Motion: Rob Hockmuth
Second: David Batluck

PerformRx will update the criteria and formulary/PDL with any changes

Add to the Tier 4 with drug specific PA requirement for [REDACTED] CHC:

- Tecartus

[REDACTED]

[REDACTED]

Add to Tier 4 with a PA requirement for [REDACTED] CHC:

- Besremi
- Fyarro
- Leqvio
- Ryplazim
- Voxzogo
- Vyvgart

[REDACTED]

[REDACTED]

				
--	---	--	--	--

	<p>[REDACTED]</p> <p>Remain non-formulary/non-preferred for [REDACTED] CHO [REDACTED]:</p> <ul style="list-style-type: none"> • Rethymic • Stratagraft <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>10. Prior Authorization Criteria Review:</p>				
<p>A. Prior Authorization Criteria Annual Review</p>				

Adrenal Enzyme Inhibitors
for Cushing's Disease

**PerformRx makes the following
recommendation:**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

CHC:





- Lower required baseline urinary free cortisol level to ≥ 1.3 upper limit of normal to align with new manufacturer data

Committee approved as
recommended

Motion: Kirton Caton
Second: Kirby Smith

PerformRx will update the
criteria and formulary/PDL
with any changes

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

				
Alpha-1 Proteinase Inhibitors (Human)	<p>PerformRx makes the following recommendation:</p>   	Committee approved as recommended Motion: Kirt Caton Second: Kirby Smith		PerformRx will update the criteria and formulary/PDL with any changes

[REDACTED]

[REDACTED]

- [REDACTED] CHC:**
- Clarify alternative measurements for alpha-1 antitrypsin serum levels
 - Allow for use in and member with a FEV1 less than or equal to 65% to align with guideline recommendations.
 - Require documentation on reauthorization member is a non-smoker

[REDACTED]

	<p>[REDACTED]</p>			
Benlysta	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kirt Caton Second: Kirby Smith</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>








[REDACTED]

[REDACTED]


[REDACTED] CHC:

- Allow for prescribing by a nephrologist due to its indication for lupus nephritis
- Include additional guideline recommended immunosuppressant example drug
- Add additional requirement Benlysta will not be used concurrently with Saphnelo or similar agents

[REDACTED]

				
Blincyto	<p>PerformRx makes the following recommendation:</p>  <p>    </p>	<p>Committee approved as recommended</p> <p>Motion: Kirt Caton Second: Kirby Smith</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none">[REDACTED][REDACTED]			
[REDACTED]	<ul style="list-style-type: none">[REDACTED][REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	<ul style="list-style-type: none">[REDACTED][REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]			
--	---	--	--	--

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>1 [REDACTED]</p> <p>2 [REDACTED]</p>			
[REDACTED]	<p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
[REDACTED]	<p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>

[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
B. Prior Authorization Criteria Annual Review without Clinical Changes				
Amifampridine	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Approve the Amifampridine prior authorization criteria <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>		<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>		
<p>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the Cystic Fibrosis transmembrane conductance regulator (CFTR) Modulators with no changes <p>[REDACTED]</p>			
<p>Dendritic Cell Tumor Peptide Immunotherapy (Provenge)</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the Dendritic Cell Tumor Peptide Immunotherapy with no changes <p>[REDACTED]</p>			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>







	<p>██████████</p>			
██████████	<p>██████████</p> <p>██████████</p> <p>██████████</p> <p>██████████</p> <p>██████████</p>	<p>██████████</p> <p>██████████</p>		<p>██████████</p>
██████████	<p>██████████</p> <p>██████████</p>	<p>██████████</p> <p>██████████</p>		<p>██████████</p>

[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>			
Naglazyme	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) Agents prior authorization criteria with no changes <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper</p>		<p>No Changes</p>

	<p>[REDACTED]</p>			
Natpara	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the Natpara prior authorization criteria with no changes <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper :</p>		No Changes

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>

				
Transthyretin-mediated Amyloidosis Agents	<p>PerformRx makes the following recommendation:</p>      CHC:	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper</p> <p>Dr. Peterson has to recuse himself for Transthyretin mediated amyloidosis</p>		No Changes

	<ul style="list-style-type: none">• Approve the Transthyretin-mediated Amyloidosis Agents prior authorization criteria with no changes <p>[Redacted]</p>			
[Redacted]	<p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>		<p>[Redacted]</p>
[Redacted]	<p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>		<p>[Redacted]</p>
[Redacted]	<p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>		<p>[Redacted]</p>
[Redacted]	<p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>		<p>[Redacted]</p>

	[REDACTED]	[REDACTED]		
KF/AHC/CHC - Compound Products	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Approve the Compound Products prior authorization criteria with no changes 	<p>Committee approved as recommended</p> <p>Motion: Rob Hockmuth Second: Donald Cooper</p>		No changes
C. New Prior Authorization Criteria				
Phenoxybenzamine (Dibenzylamine)	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none"> • Approve the newly developed Phenoxybenzamine prior authorization criteria • Add Phenoxybenzamine to Tier 4 with drug specific prior authorization criteria 	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Wayne Weart</p>		PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p>			
Dojolvi	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Approve the newly developed Dojolvi prior authorization criteria <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Wayne Weart</p>		<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

11. Additional Items				
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

	<p>[REDACTED]</p>			
<p>Emergency use [REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>		<p>[REDACTED]</p>
<p>12. Recalls</p>	<p>9/28/2021 – 1/13/2022</p> <p>There were no Class 1 or 2 recalls impacting all lots for medications listed within FDB or Medispan</p>	<p>Informational</p>		<p>PerformRx</p>

13. Adjourn	The meeting adjourned at 7:37 PM	N/A		Bruce Himmelstein
	The next meeting is May 2, 2022			



Bruce Himmelstein MD MBA
 VP, Utilization Management Physician

May 10, 2022

Date